Innohep (Tinzaparin Sodium)

Innohep (tinzaparin sodium) is used in the anticoagulation pathway to prevent and treat thromboembolic conditions.

• Deep vein thrombosis (DVT): prevents clot formation and facilitates clot resolution in patients at risk or with established DVT.
• Pulmonary embolism (PE): reduces the risk of embolic events and supports treatment of acute PE.
• Surgical thromboprophylaxis: lowers incidence of postoperative venous thromboembolism in patients undergoing major surgery.
• Haemodialysis anticoagulation: provides anticoagulation during haemodialysis procedures to maintain circuit patency.

• Tinzaparin sodium binds to antithrombin III, markedly enhancing its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). This accelerated inhibition curtails thrombin generation and fibrin formation, preventing clot development and propagation. Its low molecular weight structure yields a higher anti‑Xa to anti‑IIa activity ratio, offering predictable pharmacokinetics and reduced need for routine laboratory monitoring.

Tinzaparin sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site reactions: erythema, pain, or bruising at the administration site.
• Minor bleeding: epistaxis, gum bleeding, or easy bruising.
• Elevated liver enzymes: transient increases in hepatic transaminases.
• Nausea or abdominal discomfort: occasional gastrointestinal upset.

Serious or Rare Side Effects

• Major hemorrhage: life‑threatening bleeding such as intracranial or gastrointestinal.
• Thrombocytopenia: heparin‑induced thrombocytopenia (HIT) with platelet count drop.
• Allergic reactions: anaphylaxis, urticaria, or angioedema.
• Spinal/epidural hematoma: bleeding in spinal canal after neuraxial procedures.

Before initiating tinzaparin therapy, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: adjust dose or monitor anti‑Xa levels in patients with severe kidney dysfunction.
• Bleeding risk: evaluate history of active bleeding, recent surgery, or coagulopathy.
• Concomitant anticoagulants: avoid or closely monitor use with other anticoagulants or antiplatelet agents.
• Pregnancy: category B, use only if benefit outweighs potential risk to fetus.
• Spinal procedures: postpone neuraxial anesthesia or puncture until anticoagulant effect has subsided.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium can interact with other medicines, altering its anticoagulant effect or increasing bleeding risk.

Major Interactions (Avoid)

• Concurrent use with warfarin or direct oral anticoagulants: markedly increased bleeding risk.
• Combination with antiplatelet drugs (e.g., clopidogrel, aspirin) at full doses: synergistic anticoagulation.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) or corticosteroids: heightened hemorrhagic potential.

Moderate Interactions (Monitor Closely)

• Heparin flushes or low‑dose unfractionated heparin: additive anti‑Xa activity.
• Thrombolytic agents (e.g., alteplase): increased risk of major bleeding.
• Certain antibiotics (e.g., vancomycin) that may affect platelet function: monitor for bleeding.